Surveillance in the digestive tract by capsule endoscopy after administration of immune checkpoint inhibitors

Surveillance in the digestive tract by capsule endoscopy after administration of immune checkpoint inhibitors - Surveillance in the digestive tract after immunotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022149

Enrollment

Registered

2016-07-16

Start date

2016-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms (Malignant melanoma, Non-small cell lung cancer, and so on)

Interventions

Capsule endoscope

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with planned immunotherapy or after administration of immune checkpoint inhibitors (within 28 days)

Exclusion criteria

Exclusion criteria: 1. Pregnant female. 2. Patients with cardiac pacemakers or other medical electronic equipment. 3. Patients who have history of the ileus or stricture or fistula of the intestine. 4. Diagnosed or suspected Crohn&#39;s disease. 5. Patients with peritoneal dissemination. 6. Patients who are unsuccessful or difficult to perform esophagogastroduodenoscopy, colonoscopy, and small-bowel endoscopy. 7. Patients with dysphagia. 8. Allergy for mosapride, dimethicone, and low-volume polyethylene glycol solution (Moviprep). 9. Other conditions not suitable for this study.

Design outcomes

Primary

Measure	Time frame
Endoscopic findings and Prevalence rate	—

Countries

Japan

Contacts

Public ContactKenro Hirata

Keio University School of Medicine Gastroenterology and Hepatology

kenro916@gmail.com03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026